<DOC>
	<DOCNO>NCT01128218</DOCNO>
	<brief_summary>Extent resection important prognostic factor affect survival individual diagnose malignant glioma . However , infiltrative nature malignant glioma tumor cell produce indistinct border normal malignant tissue , lack easily identifiable tumor margin confound attempt total resection . The investigator propose identify border malignant glioma intraoperatively use oral 5-aminolevulinic Acid ( 5-ALA ) result fluorescence malignant cell thereby provide opportunity complete tumor resection . When exogenous 5-ALA provide increased concentration tumor cell become fluorescent ultraviolet light . This feature identify tumor cell intraoperatively facilitate complete resection . Data collection include measurement dose-limiting toxicity , tumor fluorescence , tumor density . Data analysis evaluate toxicity , sensitivity , specificity 5-ALA. Time-to-progression , one year survival rate total survival measure function extent resection . ( Details Detailed Description . ) Following completion phase 1 portion trial , additional 15 subject enter recommended phase 2 dose level order define parameter recommend phase 2 dose level .</brief_summary>
	<brief_title>A Study Specificity Sensitivity 5- Aminolevulinic Acid ( ALA ) Fluorescence Malignant Brain Tumors</brief_title>
	<detailed_description>Specific Aims : This study intend investigate utility , safety efficacy 5-aminolevulinic acid ( 5-ALA ) induce brain tumor fluorescence malignant brain tumor resection . Specifically study intend : Establish safe dose oral 5-ALA administration . Determine sensitivity specificity 5-ALA mediate fluorescence malignant glioma tissue brain . Compare neurosurgeon 's intra-operative estimate extent malignant glioma resection ( guided tumor fluorescence ) actual extent resection determine post-operative imaging . Compare time-to-progression survival comparable case perform without aid 5-ALA. Background Significance : There considerable body literature suggest completeness resection positive factor long term survival individual malignant glioma . Unfortunately , often difficult completely remove malignant brain tumor surgery sometimes difficult distinguish tumor normal brain . It would helpful would way help surgeon make distinction . Malignant glioma tumor cell ( normal cell ) contain biosynthetic pathway produce protoporphyrin naturally occur amino acid , 5-aminolevulinic acid ( 5-ALA ) . Protoporphyrin immediate precursor hemoglobin ( hemoglobin without iron atom ) fluorescent blue light . When exogenous 5-ALA provide increased concentration , protoporphyrin concentration malignant cell increase rate far great normal brain cell render malignant cell fluorescent red blue light . This feature distinguish tumor cell normal cell intraoperatively facilitate complete resection . Recent study Germany confirm utility pre-operative oral 5-ALA intraoperative brain tumor fluorescence aid resection brain tumor individual malignant brain tumor . These study lead oral 5-ALA approve indication European Medicines Agency ( The European Medicines Agency comment approval find : http : //www.emea.europa.eu/humandocs/PDFs/EPAR/gliolan/H-744-en6.pdf ) , oral 5-ALA approved indication United States FDA . This proposal phase 1 phase 2 trial hopefully lead FDA approval oral 5-ALA intra-operative visualization malignant brain tumor . Experimental Plan Methods : In phase 1 part propose study , minimum 3 maximum 18 patient administered oral 5-ALA 4 hour prior surgery cohort 3 five escalating dos 5-ALA ( 10 , 20 , 30 , 40 , 50 mg/kg ) . The following data collect : - Dose-limiting toxicity data ; i.e. , nausea , vomit , liver function , photo-sensitivity , survival - Tumor fluorescence assess neurosurgeon ( 0 +++ ) three distinct area fluorescence ( Strong fluorescence , Weak fluorescence , No fluorescence ) - Tumor density biopsy obtain neurosurgeon three distinct area fluorescence assess neuropathology ( Solid tumor , Tumor mix infiltrate normal brain , No tumor ) - Neurosurgeon 's intra-operative estimate residual tumor - Neuroradiologist 's estimate post-operative residual tumor MRI - Time progression MRI - Survival ( time progression , one year survival rate total survival ) This trial evaluate : - single dose toxicity oral 5-ALA give pre-operatively ; - sensitivity specificity 5-ALA - Protoporphyrin IX ( Pp IX ) intraoperative fluorescent detection agent aid resection tumor tissue remain wall resection cavity primary recurrent malignant brain tumor ; - relationship neurosurgeon 's estimate extent malignant glioma resection ( guided tumor fluorescence ) actual extent resection determine post-operative imaging ; - time-to-progression , one year survival rate total survival function extent resection . Following completion phase 1 portion trial , additional 15 subject enter recommended phase 2 dose level order define parameter recommend phase 2 dose level . Discussions statistician lead development number 2x2 table 3x3 table data analysis lead establishment sensitivity specificity fluorescence-guided brain tumor resection compare conventional brain tumor resection technique .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Patients must clinically document primary brain tumor resection clinically indicate . Age â‰¥ 18 year . Because dose adverse event data currently available use 5ALA patient &lt; 18 year age , child exclude study eligible future pediatric phase 1 singleagent trial ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % ) Normal organ marrow function define : Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Creatinine within normal institutional limit OR Creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Agreement woman childbearing potential men use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Ability understand willingness sign write informed consent document Patients may receive investigational agent time entry study History allergic reaction attribute compound similar chemical biologic composition 5ALA Personal family history porphyria Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study 5ALA unknown teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother 5ALA , breastfeed discontinue mother treat 5ALA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Brain Neoplasms</keyword>
	<keyword>5-ALA</keyword>
	<keyword>Aminolevulinic acid</keyword>
	<keyword>Fluorescence</keyword>
	<keyword>Gliomas</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Surgery</keyword>
</DOC>